C12N 2760/20234
Use of virus or viral component as vaccine
Official title: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2760/20234 (Use of virus or viral component as vaccine) appears on 67 US grants and 107 published applications in this corpus.
Search patents in C12N- Granted patents
- 67
- Published applications
- 107
- Assignees
- 71
- Inventors
- 197
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 1 | 2 |
| 2003 | 3 | 2 |
| 2004 | 1 | 4 |
| 2005 | 1 | 2 |
| 2006 | 4 | 1 |
| 2007 | 1 | 2 |
| 2008 | 0 | 3 |
| 2009 | 4 | 5 |
| 2010 | 2 | 6 |
| 2011 | 2 | 4 |
| 2012 | 5 | 5 |
| 2013 | 0 | 3 |
| 2014 | 3 | 6 |
| 2015 | 0 | 4 |
| 2016 | 4 | 4 |
| 2017 | 6 | 6 |
| 2018 | 2 | 3 |
| 2019 | 2 | 3 |
| 2020 | 4 | 5 |
| 2021 | 3 | 8 |
| 2022 | 4 | 2 |
| 2023 | 3 | 8 |
| 2024 | 1 | 11 |
| 2025 | 5 | 6 |
| 2026 | 2 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Oncolytic virus in combination with immune checkpoint inhibitor for treating tumors15 Sep 2026US 12,734,202 B2Joint Biosciences (Sh) Ltd.
- Unified platform for rapid production of nanovaccines with enhanced safety, efficacy and precision9 Jun 2026US 12,651,648 B2Santa Clara University
- Activation of resident memory T cells for cancer immunotherapy23 Dec 2025US 12,502,406 B2Regents of the University of Minnesota
- Oncolytic virus vaccine and drug for treating tumors by combining oncolytic virus vaccine with immune cells16 Dec 2025US 12,496,337 B2Joint Biosciences (Sh) Ltd.
- Compositions and methods for treatment of cytomegalovirus23 Sep 2025US 12,421,283 B2Variation Biotechnologies Inc.
- Activation of resident memory t cells for cancer immunotherapy28 May 2026US 2026/0144820 A1New York Society for the Relief of the Ruptured and Crippled, maintaining the Hospital for Special
- Self-replicating rna vaccines and methods of use8 Jan 2026US 2026/0007738 A1Immorna (Hangzhou) Biotechnology Co., Ltd.
- Modified varicella zoster virus glycoprotein e proteins23 Oct 2025US 2025/0325656 A1Glaxosmithkline Biologicals SA
- Multivalent display on enveloped particles with human oligomerization domains18 Sep 2025US 2025/0288662 A1Achelois Biopharma, Inc.
- Tissue and cell-type specific delivery of therapeutic molecules incorporating viral and human fusiogenic proteins5 Jun 2025US 2025/0177555 A1The Regents of the University of Colorado, a body corporate
Most cited
By later US patents
- Preparation of inactivated viral vaccines92US 4,693,981 AAdvanced Genetics Research Institute · 1987
- Preparation of inactivated viral vaccines49US 5,106,619 ADiamond Scientific Co. · 1992
- Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA49US 7,045,313 B1The United States of America as represented by the Department of Health and Human Services · 2006
- Signal for packaging of influenza virus vectors47US 7,226,774 B2Wisconsin Alumni Research Foundation · 2007
- Recombinant poxviruses having foreign DNA expressed under the control of poxvirus regulatory sequences46US 6,998,252 B1The United States of America as represented by the Department of Health and Human Services · 2006